A micro-ribonucleic acid signature associated with recovery from assist device support in 2 groups of patients with severe heart failure.
نویسندگان
چکیده
OBJECTIVES This study was conducted to test the hypothesis that cardiac micro-ribonucleic acid (miR) profiling in severe heart failure patients at the time of ventricular assist device (VAD) placement would differentiate those who remained VAD-dependent from those with subsequent left ventricular (LV) recovery. BACKGROUND The relationship of myocardial miR expression to ventricular recovery is unknown. METHODS We studied 28 patients with nonischemic cardiomyopathy requiring VAD support consisting of test and validation cohorts from 2 institutions: 14 with subsequent LV recovery and VAD removal and 14 clinically matched VAD-dependent patients. Apical core myocardium was studied for expression of 376 miRs by polymerase chain reaction (PCR) array and real-time-PCR methods. Samples from 7 nonfailing hearts were used in confirmatory studies. RESULTS By PCR array, 10 miRs were differentially expressed between LV recovery and VAD-dependent patients in the test cohort. The real-time PCR confirmed lower expression in LV recovery patients for 4 miRs (15b, -1.5-fold; 23a, -2.2-fold; 26a, -1.4-fold; and 195, -1.8-fold; all p < 0.04 vs. VAD dependent). The validation cohort similarly showed lower miRs expression in LV recovery patients (23a, -1.8-fold; and 195, -1.5-fold; both p < 0.03). Furthermore, miR 23a and 195 expression in nonfailing hearts was similar to LV recovery patients (both p < 0.04 vs. VAD dependent). The LV recovery patients also had significantly smaller cardiomyocytes by quantitative histology in both cohorts. CONCLUSIONS Lower cardiac expression of miRs 23a and 195 and smaller cardiomyocyte size at the time of VAD placement were associated with subsequent LV functional recovery. Differential expression of miRs at VAD placement may provide markers to assess recovery potential.
منابع مشابه
Application of centrifugal pump in right ventricular failure due to pulmonary artery hypertension. (A case report)
Background: It has not been yet developed a ost suitable method to treat right ventricular failure due to pulmonar artery hypertention resulted from ventricular arrhythia. Though some case reports about patients ready to heart transplant using left assist device or biventral assist device as bridge have been published in Journals, but nocase concerning application of centrifugal pump for treatm...
متن کاملنتایج کاربرد بالون پمپ داخل آئورت در بیماران جراحی قلبIntra-Aortic Ballon Pump Outcome in Cardiac Surgical Patients
Background & Aim: Intra-aortic ballon pump(IABP) is a mechanical device that has become an accepted treatment modality for patients with severely compromised hemodynamics. The present retrospective study was undertaken to identify the major survival and nonsurvival determinants of patients who were in need of intra-aortic ballon pump support after cardiac surgery. Patients & Methods: Th...
متن کاملImprovement of Left Ventricular Assist Device (LVAD) in Artificial Heart Using Particle Swarm Optimization
In this approach, the Left ventricular assist pump for patients with left ventricular failure isused. The failure of the left ventricle is the most common heart disease during these days. Inthis article, a State feedback controller method is used to optimize the efficiency of a samplingpump current. Particle Swarm Algorithm, which is a set of rules to update the position andvelocity, is applied...
متن کاملDesign an Equivalent Left Ventricular Assist Device for Medical Equipment Labs
LVAD is a mechanical pump supporting a weak heart function and blood flow. Sometimes, the heart may not recover fast enough to take over the pumping action immediately after surgery, in such patients a temporary support device has been employed to maintain the pumping action until the patient’s own heart recovers. This device can be considered as a temporary alternative before the process of ar...
متن کاملMolecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy.
AIMS A novel combination therapy consisting of a left ventricular assist device (LVAD) combined with pharmacologic therapy including the selective beta(2)-agonist, clenbuterol, has shown promise in restoring ventricular function in patients with heart failure. The aim of this study was to identify common genes and signalling pathways whose expression was associated with reversal of heart failur...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of the American College of Cardiology
دوره 58 22 شماره
صفحات -
تاریخ انتشار 2011